Prelude Therapeutics Incorporated (PRLD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Prelude Therapeutics Incorporated (PRLD) is Neutral.

The composite score behind that read is -0.01, weighing +0.14 of bullish evidence against -0.22 bearish.

Prelude Therapeutics Incorporated last closed at $3.89, +0.26% on the session.

Against the IVW growth benchmark the position is -0.54% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

Prelude Therapeutics Incorporated has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Prelude Therapeutics Incorporated in the 14th percentile on return on equity, where 100 is best.

Prelude Therapeutics Incorporated is classified under Health Care / Biotechnology, with a market capitalisation of $309.64M.

StockMap tracks Prelude Therapeutics Incorporated as the 210th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Prelude Therapeutics Incorporated ranks 117th of 381 in the group, against a group median of -0.08.